Three prominent research institutions—two in America and one in Brazil—received a 5-year, $8.3 million research grant from the National Cancer Institute (NCI) to investigate strategies to prevent HPV-related cancers among individuals with HIV. Weill Cornell Medicine and Moffitt Cancer Center in the U.S., and Universidade de Sao Paulo in Brazil, will receive the funds to design and implement three clinical trials that focus on oropharyngeal cancer and cervical cancer. Both malignancies are caused by HPV infections, and rates of these cancer are higher among people with HIV.
In the first clinical trial, the investigators will seek to understand if the HPV 9-valent vaccine (Gardasil 9, Merck) can prevent oral HPV infections among men with HIV. While the second study focuses on rapid “point-of-care” screening tests to augment the detection of cervical premalignant lesions, the third study investigators will evaluate the effectiveness of a novel therapeutic vaccine, reports Healio.
An NCI Multinational Partnership
The Multinational Partnership to Prevent HPV Associated Cancer in People Living with HIV brings together experienced research sites and world renowned HPV and HIV investigators to build on established collaborations to conduct clinical trials on prevention of HPV-associated cancers among people living with HIV. According to the NCI, it represents an invaluable opportunity for newer investigators from Latin America/Caribbean (LAC) to participate and learn from high quality research. Timothy J. Wilkin, Weill Medical College of Cornell, leads the effort.
Timothy J. Wilkin, associate professor of medicine, division of infectious diseases, Weill Cornell Medicine and Infectious disease specialist at NewYork-Presbyterian/Weill Cornell Medical Center
Anna R. Giuliano, PhD, founding director of Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center
Luisa Lina Villa, PhD, associate professor, department of radiology and oncology, Universidade de Sao Paulo